🇺🇸 Roivant Sciences Ltd.ROIV

Investor Event Form 8-K 21-10-2026 07:05:44 EDT

Subject: 8-K Items 7.01, 9.01

Overview: Announced positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis, with a planned sNDA filing in the first half of 2027.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest